Cytokine concentrations in people with eating disorders: A comprehensive updated systematic review and meta-analysis
Abstract
Prior research has found altered levels of cytokines in people with eating disorders (EDs). This study is an update of a previous meta-analysis, including longitudinal analyses and machine learning heterogeneity analyses (MetaForest). This pre-registered (https://osf.io/g6d3f) systematic review and meta-analysis following PRISMA guidelines assessed studies from four databases (PubMed, Web of Science, MEDLINE, PsycINFO) reporting cytokine concentrations in people with EDs until 10th November 2024. Random-effects models were utilised for all meta-analyses. Twenty-four new studies are incorporated, resulting in a total of 43 studies included in meta-analyses. Interleukin (IL)−6 and IL-15 are higher, and IL-7 lower, in anorexia nervosa (AN) compared with controls. When controlling for outliers, tumour necrosis factor (TNF)-α, IL-1β, IL-4, IL-8, IL-10, interferon (IFN)-γ, monocyte chemoattractant protein (MCP) and transforming growth factor (TGF)-β are similar between AN and controls. Longitudinally, IL-6 is lower in AN at follow-up compared to baseline, although this may be an artefact of publication bias. TNF-α and IL-1β do not change longitudinally. There are largely no differences in IL-6 and TNF-α in bulimia nervosa (BN) and there are insufficient studies to perform meta-analyses for binge eating disorder or other EDs. In acute AN, concentrations of IL-6 and IL-15 are elevated and IL-7 is decreased, with preliminary but unconclusive evidence for small decreases in IL-6 over…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 7 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.